However, although durable responses to PD-1/PD-L1 therapies have been observed in a range of cancers including melanoma, non-small cell lung cancer, and renal cell carcinoma [36], reliable biomarkers to predict who will respond to immune blockade are still lacking. This evidence concerns the gene CD274 and hereditary clear cell renal cell carcinoma.